Novo Nordisk Cuts Ozempic and Wegovy Prices

This is a corporate pricing decision by a private pharmaceutical company with zero constitutional implications. A-score: All drivers score 0 as there is no mechanism affecting elections, rule of law, separation of powers, civil rights, institutional capture, corruption, or violence. This is a voluntary business decision, not government action. No constitutional damage pathway exists. B-score: Layer 1 yields 4.4 (outrage_bait:1 for mild affordability angle, meme_ability:2 for Ozempic cultural presence, novelty:2 for price cut announcement, media_friendliness:3 for health/pharma interest). Layer 2 adds 0.45 (timing:1 for potential political pressure context, others 0). With 0% intentionality modulation, final B-score is 4.85. Classification: Both scores well below thresholds (A=0, B=4.85). No constitutional mechanism present. This is routine corporate news about future pricing strategy responding to market/political environment pressures, not a constitutional event.